Kuros Biosciences Ltd. (CSBTF)
OTHER OTC:CSBTF
CSBTF Stock Chart & Stats
$35.00
$0.26(0.95%)
At close: 4:00 PM EST
$35.00
$0.26(0.95%)
Day’s Range― - ―
52-Week Range$23.28 - $42.81
Previous CloseN/A
Volume4.47K
Average Volume (3M)469.00
Market Cap
$997.77M
Enterprise Value$761.29M
Total Cash (Recent Filing)$15.66M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)468.8
Beta0.58
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding39,439,423
10 Day Avg. Volume795
30 Day Avg. Volume469
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue5.88
Enterprise Value/Gross Profit6.75
Enterprise Value/Ebitda74.66
Forecast
1Y Price Target
$47.95Price Target Upside37.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.4
Revenue Forecast (FY)$256.27M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & High Gross MarginsSustained revenue expansion from ~4m to ~121m and very high gross margins indicate durable product-market fit and strong unit economics. High gross margins provide operating leverage to fund commercialization and R&D while insulating profitability against moderate cost swings.
Profitability Inflection In 2025Transitioning to positive operating and net income in 2025 shows the business model can reach sustainable profitability as scale increases. A durable inflection reduces reliance on continual capital raises and demonstrates fixed-cost absorption from growing product sales.
Conservative Balance Sheet / Low LeverageVery low leverage and rising assets provide financial flexibility to invest in commercialization or absorb short-term cash stress. Conservative financing reduces default risk and supports strategic options (partnerships, targeted capex) without urgent refinancing needs.
Bears Say
Weak Cash ConversionEarnings improved but cash flows weakened, suggesting working-capital or capex drains. Persistent negative operating and free cash flow raises funding sensitivity, may force external financing, and can limit reinvestment into sales and clinical support long-term.
Thin Net Margins And Limited CushionNet margins near 1.7% leave little buffer against pricing pressure, input cost increases, or slower growth. With limited profitability cushion, a modest revenue setback or margin compression could quickly reverse the recent earnings inflection and hinder long-term return generation.
Concentration On MagnetOs And Spine Market AdoptionHeavy reliance on a single product category and the U.S. spine channel concentrates demand risk. Durable growth depends on sustained surgeon adoption and favorable hospital contracting; competitive alternatives or slower uptake could materially pressure long-term revenue trajectories.
Kuros Biosciences News
CSBTF FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was $23.28 and its highest was $42.81 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is $997.77M.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 56 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported $0.118 earnings per share for the quarter, beating the consensus estimate of $0 by $0.118.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,439,423 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of $0.118 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went up 10.105%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CSBTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
CSBTF Company Deck
CSBTF Earnings Call
Q4 2026
0:00 / 0:00
CSBTF Stock 12 Month Forecast
Average Price Target
$47.95
▲(37.00% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Ownership Overview
―
Insiders
0.77% Mutual Funds
― Other Institutional Investors
97.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---